Sol ventrikül hipertrofisine yeni bir tedavi yaklaşımı
Articles > Article · 1998
Authors: Dilek Soysal, Aslı KILAVUZ, Ayşenur Atay, Ayça Öztin, Levent Kurşun, Hüseyin Arı
Medical Network Kardiyoloji, Other Refereed National Journals, National, TR DİZİN (ULAKBİM), 1998, vol 5, pp 133-136
Summary
<p>A new therapeutic approach to left ventricular hypertrophy</p><p>Öz (İngilizce):In general drugs that influence renin angiotensin aldosterone system (RAAS) has been shown to reduce left ventricular hypertrophy (LVH). We investigated the effects of Losartan -K+ an angiotensin II (Ang II) receptor antagonist, on LVH, plasma renin activity (PRA), serum aldosterone levels and blood pressure levels.37 patients, M/F was 17/20, aged 35-70 years with a systolic blood pressure (SBP) of 140 mmHg or more and/or diastolic blood pressure (DBP) between 90 to 115 mmHg were included in the study. All had echocardiographic evidence of LVH. Following 2 weeks washout period baseline echocardiography was performed to get left ventricular dimensions. PRA and serum aldosterone levels were measured simultaneously. After 6 months of treatment with 50 mg ofLosartan daily, the parameters mentioned above were controlled again, there was a significant decrease in SBP, DBP and serum aldosterone levels (P&lt;0.001), but a moderate decrease in PRA, left ventricular mass (LVM) and left ventricular mass index (LVMI) (P&lt;0.05). In conclusion, we can say Ang II receptor blockade may be expected to provide more comprehensive blockade of the trophic actions of Ang II.</p>